Evidence map›Paper›PMID 39993199›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Reply to Trollmann et al.: Perspective on LNP structure and simulation.

Adiran Garaizar, David Díaz-Oviedo, Nina Zablowsky, Sami Rissanen, Johannes Köbberling, Jiawei Sun, Christoph Steiger, Patrick Steigemann, Florian A Mann, Katharina Meier

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Adiran GaraizarDrug Discovery Sciences, Bayer Pharmaceuticals, Wuppertal 42113, Germany.
David Díaz-OviedoDrug Discovery Sciences, Bayer Pharmaceuticals, Wuppertal 42113, Germany.ORCID 0000-0003-0499-2863
Nina ZablowskyLead Discovery, Nuvisan Innovation Campus Berlin, Berlin 13353, Germany.ORCID 0009-0007-1289-3925
Sami RissanenChemical and Pharmaceutical Development, Bayer Pharmaceuticals, Turku 20210, Finland.
Johannes KöbberlingDrug Discovery Sciences, Bayer Pharmaceuticals, Wuppertal 42113, Germany.
Jiawei SunChemical and Pharmaceutical Development, Bayer Pharmaceuticals, Berlin 13353, Germany.
Christoph SteigerChemical and Pharmaceutical Development, Bayer Pharmaceuticals, Berlin 13353, Germany.
Patrick SteigemannLead Discovery, Nuvisan Innovation Campus Berlin, Berlin 13353, Germany.ORCID 0000-0003-4748-3989
Florian A MannChemical and Pharmaceutical Development, Bayer Pharmaceuticals, Berlin 13353, Germany.ORCID 0000-0003-2348-1663
Katharina MeierDrug Discovery Sciences, Bayer Pharmaceuticals, Wuppertal 42113, Germany.ORCID 0000-0003-2474-8278

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39993199
PMCPMC11892676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.